Overview

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a multi- centered two-stage Pilot Study assessing the tolerability and toxicity of an alternating regimen of FOLFOX and FOLFIRI for the treatment of newly diagnosed and untreated metastatic pancreatic cancer in patients over the age of 65 years.
Phase:
Phase 2
Details
Lead Sponsor:
Fox Chase Cancer Center
Treatments:
Folfirinox